Do you have a child or teen suffering from migraine?

Pediatric Migraine Clinical Trial

Biohaven Pharmaceuticals is studying an investigational drug, called rimegepant, for the acute treatment of migraines in the pediatric population. If your child is between 12 and 17 years of age and has at least a 6-month history of migraine, they may qualify. The investigational drug, plus all study-related assessments, will be provided at no cost to you.

Health insurance is not required to take part in this study and compensation for participation may also be provided.

Who is this study for?

Teens may qualify for this study if they meet the following criteria:

Between the ages of 12 and 17

Have at least 1 migraine per month

Have at least a 6-month history of migraine

The migraine study clinicians will further assess medical and migraine history to determine eligibility.  

Participants may receive:

Study-related evaluations and care, including the investigational study drug.*

Compensation for participation may be provided.

*Insurance not needed to participate.

teenage boy.jpg

How can my child participate?


Take the self-assessment* to see if your child meets the basic criteria.

*Only parents or guardians should complete the assessment


Enter your contact information

After you submit your information, the research center closest to you will review your responses and reach out to you to talk in more detail.